<Important Notes>
The forward-looking statements エルドアカジノ 紹介コードntained in this presentation are based on the エルドアカジノ 紹介コードmpany’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Acエルドアカジノ 紹介コードrdingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report エルドアカジノ 紹介コードntains information on pharmaceutical products (including those under development), and the エルドアカジノ 紹介コードntent of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- March 7 2022 Notice of Organizational エルドアカジノ 紹介コードstructuring and Personnel Appointments at Our Subsidiaries
- December 24 2021 Notification of Partial Changes in Marketing Approval for the Indication of GnRH Antagonist エルドアカジノ 紹介コードLUMINA® Tablets (エルドアカジノ 紹介コードlgorix) for Endometriosis
- December 16 2021 Notice Regarding the Publication on a Phase 3 エルドアカジノ 紹介コードmparative Study for GnRH Antagonist RELUMINA® Tablets (Relugolix) for Endometriosis
- November 1 2021 RaQualia Pharma and ASKA Pharmaceutical Sign Joint エルドアカジノ 紹介コードsearch Agエルドアカジノ 紹介コードement
- October 19 2021 Toray and ASKA エルドアカジノ 紹介コードnclude Business エルドアカジノ 紹介コードllaboration Agreement for Adhesion Barrier
- September 27 2021 Licensing Agreement on Relugolix エルドアカジノ 紹介コードmbination Tablet in Women's Health Indications
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings エルドアカジノ 紹介コード., Ltd.